BerGenBio to hold business update conference call

- Management to provide clinical and financial updates, and outline proposed rights issue -

- Webcast will take place on Monday, May 15, 2023, at 10 a.m. CEST -


BERGEN, Norway, May 9, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that it will hold a business update conference call on Monday, May 15, 2023, at 10 a.m. CEST. BerGenBio’s senior management team will provide a briefing via a webcast presentation on the Company’s website, followed by a Q&A session.


Topics to be addressed during the presentation include:


Proposed Rights Issue: The Company announced on April 25, 2023, its intentions to carry out a partially underwritten rights issue to raise gross proceeds of up to NOK 250 million.

A Q&A document pertaining to the rights issue can from today be found in the General Meetings portion of the Investors section of  


BGBC008 Additional Data: Additional results of pre-planned analyses from the Phase 2 BGBC008 trial evaluating bemcentinib in combination with pembrolizumab in 2L+ NSCLC patients will be presented.


BGBC003 Topline Data: Topline data will be presented from the Phase 2 BGBC003 trial evaluating bemcentinib in combination with chemotherapy in patients with AML and as a single agent in patients with MDS.


Financial Update: An update on the Company’s key financial numbers will be provided as part of the business update.

Full first quarter 2023 financial results report will currently not be prioritized and release will be delayed to 22 June 2023.


The webcast link will be available at in the Investors/Financial Reports section.

A recording will be available shortly after the webcast has finished. 








Martin Olin CEO, BerGenBio ASA


Rune Skeie, CFO, BerGenBio ASA


Investor Relations / Media Relations


Graham Morrell


Media Relations


Jan Lilleby

+47 90 55 16 98


About BerGenBio ASA


BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections.


BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit


Forward looking statements


This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.


This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.